MetLife Investment Management LLC Purchases 3,135 Shares of IVERIC bio, Inc. (NASDAQ:ISEE)

MetLife Investment Management LLC lifted its position in IVERIC bio, Inc. (NASDAQ:ISEE – Get Rating) by 5.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 62,383 shares of the company’s stock after acquiring an additional 3,135 shares during the period. MetLife Investment Management LLC owned 0.05% of IVERIC bio worth $1,119,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Trexquant Investment LP purchased a new position in shares of IVERIC bio in the 2nd quarter worth $704,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in IVERIC bio by 31.3% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,106 shares of the company’s stock valued at $3,310,000 after acquiring an additional 82,092 shares during the period. Barclays PLC raised its holdings in IVERIC bio by 2,216.1% during the third quarter. Barclays PLC now owns 330,550 shares of the company’s stock valued at $5,930,000 after acquiring an additional 316,278 shares during the period. DekaBank Deutsche Girozentrale raised its holdings in IVERIC bio by 48.9% during the second quarter. DekaBank Deutsche Girozentrale now owns 115,700 shares of the company’s stock valued at $1,092,000 after acquiring an additional 38,000 shares during the period. Finally, Driehaus Capital Management LLC raised its holdings in IVERIC bio by 32.1% during the second quarter. Driehaus Capital Management LLC now owns 1,116,401 shares of the company’s stock valued at $10,740,000 after acquiring an additional 271,587 shares during the period.

IVERIC bio Trading Up 1.2 %

ISEE opened at $20.78 on Wednesday. IVERIC bio, Inc. has a 12 month low of $8.85 and a 12 month high of $26.35. The company has a current ratio of 13.40, a quick ratio of 13.40 and a debt-to-equity ratio of 0.18. The stock has a 50-day moving average of $21.03 and a 200 day moving average of $19.49.

Analyst Upgrades and Downgrades

ISEE has been the topic of a number of recent analyst reports. Jefferies Financial Group cut IVERIC bio from a “buy” rating to a “hold” rating and decreased their price target for the company from $30.00 to $20.00 in a report on Thursday, November 10th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of IVERIC bio in a report on Friday, February 17th. Finally, B. Riley lifted their target price on IVERIC bio from $17.00 to $19.00 and gave the stock a “neutral” rating in a report on Tuesday, February 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.30.

Insider Buying and Selling

In other IVERIC bio news, COO Keith Westby sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, February 17th. The stock was sold at an average price of $25.05, for a total transaction of $375,750.00. Following the completion of the transaction, the chief operating officer now owns 46,354 shares in the company, valued at $1,161,167.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other IVERIC bio news, COO Keith Westby sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, February 17th. The stock was sold at an average price of $25.05, for a total transaction of $375,750.00. Following the completion of the transaction, the chief operating officer now owns 46,354 shares in the company, valued at $1,161,167.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Glenn Sblendorio sold 17,447 shares of the business’s stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $20.06, for a total value of $349,986.82. Following the transaction, the chief executive officer now owns 228,191 shares of the company’s stock, valued at approximately $4,577,511.46. The disclosure for this sale can be found here. Over the last quarter, insiders sold 93,134 shares of company stock worth $2,026,165. Corporate insiders own 2.70% of the company’s stock.

IVERIC bio Profile

(Get Rating)

IVERIC bio, Inc operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R.